Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01122602 · ClinicalTrials.gov registry record · Phase 3
Evaluate Analgesic Efficacy of Fast Release Aspirin
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 500
- Enrollment target
NCT01122602: Completed Phase 3 study, sponsored by Bayer.
NCT01122602 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 500 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (35% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01122602, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 500 participants
- Enrollment target
Study Summary
The objective of the study is to evaluate the analgesic efficacy of a single, oral dose of fast release aspirin tablets, 650 mg (2 x 325 mg) compared to regular aspirin tablets, 650 mg (2 x 325 mg) and placebo in subjects with postsurgical dental pain.
Interventions
- DRUG Placebo
- DRUG Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036)
- DRUG Acetylsalicyclic acid (Aspirin, BAYE4465)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2010-04-29 |
| Est. Completion | 2010-08-06 |
| Phase | Phase 3 |
What the finished NCT01122602 record still lists
NCT01122602 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (35% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01122602 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01122602 about?
NCT01122602 is a clinical study titled "Evaluate Analgesic Efficacy of Fast Release Aspirin". The objective of the study is to evaluate the analgesic efficacy of a single, oral dose of fast release aspirin tablets, 650 mg (2 x 325 mg) compared to regular aspirin tablets, 650 mg (2 x 325 mg) and placebo in subjects with postsurgical dental pain.
What is the current status of trial NCT01122602?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2010-04-29. Estimated completion is 2010-08-06.
What interventions are being tested in trial NCT01122602?
The interventions under investigation include: Placebo (DRUG), Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036) (DRUG), Acetylsalicyclic acid (Aspirin, BAYE4465) (DRUG).
Who is sponsoring clinical trial NCT01122602?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01122602's enrollment target sits among peer trials
500 744th of 2000 higher than 1,226 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI